You are viewing a preview of...
AUP-55 - A Lactic Acid Bacterial Treatment for Ovarian Cancer, Bladder Cancer, and Peritoneal Carcinomatosis
![](https://img.in-part.com/resize?width=1200&height=800&background=255,255,255&type=jpeg&quality=70&stripmeta=1&url=https://s3-eu-west-1.amazonaws.com/assets.in-part.com/mAtpOUPT6QncLpXlQEVg_AUP-55.jpeg)
Aurealis pre-clinical stage asset AUP-55 consists of genetically engineered lactic acid bacteria for the treatment of ovarian cancer, peritoneal carcinomatosis and bladder cancer. In ovarian cancer models in mice, treatment with AUP-55 resulted in 91.3 % survival and lower tumour load compared to 0 % survival and massively increased tumour load in untreated subjects.
Aurealis Therapeutics have provided the following sources to better demonstrate the capabilities of AUP-55:
- Product Presentation
- Relevant Publication (Journal of Clinical Oncology)
Log in or create a free account to continue reading